Massive Bio — Inaugural Strategic Investment in Rivvi for AI Healthcare Engagement
ENTITYMassive Bio, an oncology-focused AI company known for clinical trial matching, has made its inaugural strategic investment in Rivvi, a startup building end-to-end AI engagement infrastructure for healthcare. The investment marks Massive Bio's first external capital deployment, signaling a strategic expansion from its core oncology trial prescreening business into broader healthcare engagement technology. Rivvi's platform is designed to manage AI-driven patient and provider engagement across the care continuum — from initial outreach through ongoing care coordination. The combination of Massive Bio's oncology AI expertise and Rivvi's engagement infrastructure is positioned to create integrated workflows that connect trial eligibility identification with sustained patient engagement. The investment reflects a broader trend of specialized healthcare AI companies building out engagement and infrastructure layers, recognizing that clinical AI value is often limited by the inability to activate patients and providers effectively at scale. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.